Comparative Evaluation of Autologous Platelet-Rich Fibrin and Platelet-Rich Plasma in the Treatment of Three-Wall Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial.
Summary of "Comparative Evaluation of Autologous Platelet-Rich Fibrin and Platelet-Rich Plasma in the Treatment of Three-Wall Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial."
Background: The topical use of platelet concentrates is recent and its efficiency remains controversial. The present study aimed to explore the clinical and radiographical effectiveness of autologous platelet rich fibrin (PRF) and platelet rich plasma (PRP) in treatment of intrabony defects in chronic periodontitis subjects. Material and Methods: 90 intrabony defects were treated either with autologous PRF with open flap debridement or autologous PRP with open flap debridement or open flap debridement alone. Clinical and radiological parameters such as probing depth (PD), clinical attachment level (CAL), intrabony defect depth and % defect fill were recorded at baseline and 9 months postoperatively. Results: Mean PD reduction and CAL gain was greater in PRF (3.77 + 1.19 mm, 3.17 + 1.29 mm) and PRP (3.77 + 1.07 mm, 2.93 + 1.08 mm) groups than control group (2.97 ± 0.93 mm, 2.83 ± 0.91 mm). Furthermore, significantly greater percentage of mean bone fill was found in the PRF (55.41 + 11.39 %) and PRP (56.85 + 14.01 %) compared to control (1.56 ± 15.12 %). Conclusions: Within the limit of the present study, there was similar PD reduction, CAL gain and bone fill at sites treated with PRF or PRP with conventional open flap debridement. Since PRF is less time consuming and less technique sensitive it may seem as the better among the two. However, long term, multicenter randomized, controlled clinical trials will be required to know their clinical and radiographical effects over bone regeneration.
Dept of Periodontics, Govt. Dental College & Research Institute, Bangalore 560002.
This article was published in the following journal.
Name: Journal of periodontology
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22348695
- DOI: http://dx.doi.org/10.1902/jop.2012.110705
We developed a new product called titanium-prepared platelet-rich fibrin (T-PRF). The T-PRF method is based on the hypothesis that titanium may be more effective in activating platelets than the silic...
Autologous platelet concentrates are successfully adopted in a variety of medical fields to stimulate bone and soft tissue regeneration. The rationale for their use consists in the delivery of a wide ...
Platelet-rich therapies are being used increasingly in the treatment of musculoskeletal soft tissue injuries such as ligament, muscle and tendon tears and tendinopathies. These therapies can be used a...
Research into regenerative dentistry has added impetus onto the field of molecular biology. It can be documented as a prototype shift in the therapeutic armamentarium for dental disease. Regenerative ...
Periodontal regeneration is defined as the reproduction or reconstitution of a lost or injured part to restore the architecture and function of the periodontium. The ultimate goal of periodontal thera...
Autologous platelet rich fibrin matrix will release growth factors which could increase the production of dermal proteins or affect the vascularity and status of neighboring tissues. This ...
Partial-thickness and full-thickness rotator cuff tears are common soft-tissue conditions that often require surgical treatment. Initial efforts to improve tendon healing centered on impro...
This prospective randomized trial evaluated the impact of autologous keratinocytes suspended in platelet concentrates on healing skin graft donor site wounds. It was hypothesized that the...
The use of platelet rich plasma will decrease wound infection postop.
This study is a clinical, multicentric, randomised open trial. The objective is to evaluate the efficiency, in terms of wound healing speed, of peroperative application of autologous plat...
Medical and Biotech [MESH] Definitions
Retraction of a clot resulting from contraction of PLATELET pseudopods attached to FIBRIN strands. The retraction is dependent on the contractile protein thrombosthenin. Clot retraction is used as a measure of platelet function.
A rare, inherited platelet disorder characterized by a selective deficiency in the number and contents of platelet alpha-granules. It is associated with THROMBOCYTOPENIA, enlarged platelets, and prolonged bleeding time.
Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
A preparation consisting of PLATELETS concentrated in a limited volume of PLASMA. This is used in various surgical tissue regeneration procedures where the GROWTH FACTORS in the platelets enhance wound healing and regeneration.
Platelet membrane glycoprotein IIb is an integrin alpha subunit that heterodimerizes with INTEGRIN BETA3 to form PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX. It is synthesized as a single polypeptide chain which is then postranslationally cleaved and processed into two disulfide-linked subunits of approximately 18 and 110 kDa in size.